FITB
63
3
MAT
46
12
LLY
37
-3
PBI
69
4
GOOG
50
-3
DE
63
3
TDC
80
4
WAT
55
2
CRM
67
2
HD
57
2
AIV
72
2
BF.B
33
2
RHI
59
2
WY
54
4
MHK
49
4
F
58
11
DTE
56
2
PSA
58
2
SE
61
-4
EMN
60
4
FITB
63
3
MAT
46
12
LLY
37
-3
PBI
69
4
GOOG
50
-3
DE
63
3
TDC
80
4
WAT
55
2
CRM
67
2
HD
57
2
AIV
72
2
BF.B
33
2
RHI
59
2
WY
54
4
MHK
49
4
F
58
11
DTE
56
2
PSA
58
2
SE
61
-4
EMN
60
4
Financhill
Back

Regenxbio 10K Form

Sell
26

RGNX
Regenxbio

Last Price:
9.60
Seasonality Move:
-5.7%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q RGNX/Regenxbio Quarterly
2023-08-02 10Q RGNX/Regenxbio Quarterly
2023-05-03 10Q RGNX/Regenxbio Quarterly
2022-11-03 10Q RGNX/Regenxbio Quarterly
2022-08-03 10Q RGNX/Regenxbio Quarterly
2022-05-04 10Q RGNX/Regenxbio Quarterly

Receive RGNX News And Ratings

See the #1 stock for the next 7 days that we like better than RGNX

RGNX Financial Statistics

Sales & Book Value

Annual Sales: $90.24M
Cash Flow: $-40.88M
Price / Cash Flow: 0
Annual Sales: $6.09
Price / Book: 1.58

Profitability

EPS (TTM): -5.02000
Net Income (TTM): $-238.81M
Gross Margin: $53.03M
Return on Equity: -69.62%
Return on Assets: -40.82%

Regenxbio Earnings Forecast

Key Regenxbio Financial Ratios

  • The Gross Profit Margin over the past 11 years for RGNX is 58.76%.
  • The Selling, General & Administrative Expenses for RGNX have been equal to 98.06% of Gross Profit Margin.
  • The Research & Development expenses have been 257.38% of Revenue.
  • The Interest Expense is -2.60% of Operating Income.
  • The Net Earning history of RGNX is -291.99% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Regenxbio Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RGNX
CUSIP: 75901B
Website: regenxbio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.05
Quick Ratio: 2.73

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RGNX Technical Analysis vs Fundamental Analysis

Sell
26
Regenxbio (RGNX) is a Sell

Is Regenxbio a Buy or a Sell?

  • Regenxbio stock is rated a Sell
    The current Regenxbio [RGNX] share price is $9.59. The Score for RGNX is 26, which is 48% below its historic median score of 50, and infers higher risk than normal.